allmu2017년 7월 24일 월요일 팜뉴스

로그인

  |  

회원가입

pharm

검색
English News

allmu2017년 7월 24일 월요일

로그인

pharm news

English News
HOME > 영문뉴스

Zabolante for the 23rd Crown.

DongWha Pharm to release COPD cure

Leslie Chang (leslie@pharmnews.co.kr) 다른기사보기 

2015-03-20 오전 10:05 페이스북 트윗터 kakao 목록 보기 프린트

New born Korean-Made COPD remedy is entitled to DongWha Pharm as for the 23rd crown. It named ‘Zabolante’ with zabofloxacin D-aspartic acid for the main elements.

MFDS has announced the Zabolante by DongHwa Pharm. has been approved as 23rd new domestic drug on 20th March. 

Zabolante is a quinolones antibiotic mainly consisting of zabofloxacin D-aspartic acid and it is an oral medical drug for COPD.

MFDS has confirmed that this new born kid has medicinal effect on the germs that has more than 2 different types of resistance over the antibiotics.

The statistic shows 13% Koreans aged more than 40 is suffering from chronic lung disease caused by the inflammation.

MFDS has stated the drug is the 3rd entry that has a capability to cure the multi-resistance antibiotics followed by Curox by JoonWoe Pharm(2001) and Pactive by LG(2002). MFDS also spoke the current domestic trendy for R&D is to create the new drug to cure the multi-resistance antibiotics.

Zabolante has conducted the clinical phase-III over 342 of patients, using Zabofloxacin on 175 and Moxifloxacin on 167. It showed the similar medicinal effect to the case of applying of Moxifloxacin.

The recent 2 consecutive new domestic drugs development are encouraging the other domestic pharm-Co's R&D.
- Copyrights ⓒ PHARMNEWS, 무단 전재 및 재배포 금지 -

전체댓글 0

People & News